U.G.C. Alergología, Hospital Regional Universitario de Málaga, Málaga, Spain.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Milano, Italy.
J Allergy Clin Immunol Pract. 2024 Jun;12(6):1430-1433. doi: 10.1016/j.jaip.2024.04.021. Epub 2024 Apr 17.
Local allergic rhinitis (LAR) is defined by a clinical history suggestive of allergic rhinitis (AR), negativity of systemic IgE measurement and positive response to nasal allergen challenge (NAC). The term local respiratory allergy includes LAR, local allergic asthma (positive response in bronchial allergen challenge) and dual allergic rhinitis defined by the coexistence of AR and LAR. LAR worsens in severity and presence of comorbidities over time, and it is an independent entity from AR. Prevalence is higher in Mediterranean countries. LAR onset occurs during childhood in 36% of cases. Physiopathological features of LAR are: increased nasal eosinophilic inflammation, tryptase and eosinophil cationic protein, and presence of nasal specific IgE in secretions of 20-40% of subjects. A recent study demonstrated increase in sequential class switch recombination to IgE markers in mucosa of LAR with accumulation of IgE+ CD38+ plasmablasts. Moreover, there is increased expression in B cells of mucosal homing receptors CXCR3+ and CXCR4 in peripheral blood, with accumulation of Th9 and Th2 cells. NAC is the gold standard in the diagnosis of LAR. The measurement of specific IgE in nasal secretions basophil activation test or are still not suitable for diagnosis. There is ample evidence of the usefulness of allergen immunotherapy in the treatment in LAR after 4 DBPCRT in 152 patients. In conclusion, knowledge about LAR is continuously increasing, with detailed definition of physiopathological mechanisms and new phenotypes. More awareness of the disease should be promoted among different specialists, and NAC must be considered an essential diagnostic tool in any age group, including children.
局部过敏性鼻炎(LAR)的定义为:临床病史提示过敏性鼻炎(AR),全身 IgE 检测阴性,鼻变应原激发试验(NAC)阳性。局部呼吸道过敏包括 LAR、局部过敏性哮喘(支气管变应原激发试验阳性)和双重过敏性鼻炎(AR 和 LAR 共存)。随着时间的推移,LAR 的严重程度和合并症的存在会加重,且其是与 AR 不同的独立实体。地中海国家的 LAR 患病率较高。36%的病例 LAR 发生在儿童时期。LAR 的病理生理学特征为:鼻嗜酸性粒细胞炎症、类胰蛋白酶和嗜酸性粒细胞阳离子蛋白增加,20-40%的患者鼻分泌物中存在特异性 IgE。最近的一项研究表明,LAR 黏膜中发生连续类别转换重组至 IgE 标志物,IgE+CD38+浆母细胞聚集。此外,外周血中黏膜归巢受体 CXCR3+和 CXCR4 在 B 细胞中的表达增加,Th9 和 Th2 细胞积累。NAC 是诊断 LAR 的金标准。鼻分泌物中特异性 IgE 的测量或嗜碱性粒细胞激活试验目前仍不适用于诊断。在 152 例患者中进行了 4 次 DBPCRT 后,有大量证据表明过敏原免疫疗法对 LAR 的治疗有用。总之,关于 LAR 的认识不断增加,其病理生理机制和新表型的定义也更加详细。不同专业人员应提高对该病的认识,并且 NAC 必须被视为任何年龄段(包括儿童)的基本诊断工具。